Legend Biotech Corp. ADR (LEGN) News

Legend Biotech Corp. ADR (LEGN): $49.85

-0.17 (-0.34%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add LEGN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

Filter LEGN News Items

LEGN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

LEGN News Highlights

  • LEGN's 30 day story count now stands at 11.
  • Over the past 10 days, the trend for LEGN's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • The most mentioned tickers in articles about LEGN are DRUG, FUTU and JNJ.

Latest LEGN News From Around the Web

Below are the latest news stories about Legend Biotech Corp that investors may wish to consider to help them evaluate LEGN as an investment opportunity.

Legend Biotech expects 2021 adj. loss of $335.8M-$364.7M

Legend Biotech (LEGN) has reported preliminary results for 2021, expecting loss of ~$365.3M to $397.4M and adj. loss of $335.8M to $364.7M.As of Dec

Seeking Alpha | February 18, 2022

Legend Biotech Announces Preliminary Results for the Year Ended December 31, 2021

SOMERSET, N.J., February 18, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today in conjunction with an announcement to be issued by Legend Biotech’s majority shareholder, GenScript Biotech Corporation, pursuant to the rules of The Stock Exchange of Hong Kong Limited, announced preliminary, unaudited financial results for the year ended December 31, 2021.

Yahoo | February 18, 2022

Billionaire Ray Dalio Places Bet on 3 “Strong Buy” Stocks

The stock market appears to be making a transition in the these first few months of 2022, from last year’s bullish trend to a slower pace of growth this year. Headwinds are mounting – the pandemic is stubbornly persistent, inflation is high and trending higher, the Fed is getting set to raise interest rates in response, the list goes on – and so it’s natural for retail investors and experts alike to go looking for advice on how to navigate these difficult currents. And one source of advice is the circle of market gurus, the hedge fund experts who have leveraged their insight into multi-billion dollar success.

Michael Marcus on TipRanks | February 16, 2022

FDA Slams Brakes On Legend Biotech''s CAR-T Therapy Trial In Lymphoma Patients

The FDA has instituted a clinical hold on Legend Biotech Corporation''s (NASDAQ: LEGN ) Phase 1 trial for LB1901. LB1901 is the company''s investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy targeting malignant CD4+ T-cells for relapsed or refractory T-cell lymphoma (TCL). The … Full story available on Benzinga.com

Benzinga | February 15, 2022

Legend Biotech slips after FDA clinical hold on blood cancer study for CAR-T therapy

Legend Biotech (LEGN) is trading ~6% lower in the pre-market on Tuesday after the company announced that the U.S Food and Drug Administration ((FDA)) imposed a clinical hold on its Phase…

Seeking Alpha | February 15, 2022

FDA Slams Brakes On Legend Biotech's CAR-T Therapy Trial In Lymphoma Patients

The FDA has instituted a clinical hold on Legend Biotech Corporation's (NASDAQ: LEGN) Phase 1 trial for LB1901. LB1901 is the company's investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy targeting malignant CD4+ T-cells for relapsed or refractory T-cell lymphoma (TCL). The FDA indicated they would provide an official clinical hold letter to Legend Biotech by March 11. Related content: Benzinga's Full FDA Calendar. To date, one patient has been dosed in the clinical trial

Yahoo | February 15, 2022

Legend Biotech Announces FDA Clinical Hold of its Phase 1 Clinical Trial for LB1901

SOMERSET, N.J., February 15, 2022--Legend Biotech Announces FDA Clinical Hold of its Phase 1 Clinical Trial for LB1901

Yahoo | February 15, 2022

Legend Biotech hits two milestones under its deal with Janssen of J&J for CAR-T therapy

Legend Biotech (LEGN) announced the achievement of two milestones under its collaboration with Janssen Biotech of Johnson & Johnson (JNJ) for cilta-cel.Also called…

Seeking Alpha | February 11, 2022

Legend Biotech Achieves Milestone Payments in BCMA CAR-T Collaboration with Janssen

SOMERSET, N.J., February 11, 2022--Legend Biotech has achieved milestone payments under its collaboration agreement with Janssen Biotech, Inc. for ciltacabtagene autoleucel (cilta-cel).

Yahoo | February 11, 2022

Yong Rong (HK) Asset Management Ltd Buys Futu Holdings, XPeng Inc, Pinduoduo Inc, Sells ...

Investment company Yong Rong (HK) Asset Management Ltd (Current Portfolio) buys Futu Holdings, XPeng Inc, Pinduoduo Inc, Taiwan Semiconductor Manufacturing Co, Luckin Coffee Inc, sells Advanced Micro Devices Inc, Freeport-McMoRan Inc, Marathon Digital Holdings Inc, Affirm Holdings Inc, Recursion Pharmaceuticals Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Yong Rong (HK) Asset Management Ltd.

Yahoo | February 8, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4391 seconds.